Stanford Just Found Why GLP-1s Don’t Work for 1 in 10 People
Stanford researchers just published findings that roughly 1 in 10 people carry genetic variants that make GLP-1 receptor agonist drugs — Ozempic, Mounjaro, Wegovy — meaningfully less effective at lowering blood sugar. The Stanford Medicine News report describes a meta-analysis of three clinical trials showing that carriers of specific variants in the PAM gene reach […]
Once-Weekly Insulin Is Here. It’s Still Not Reversal.
The FDA just approved the first once-weekly basal insulin for Type 2 diabetes — Novo Nordisk’s Awiqli, greenlit on March 26, 2026 per the FDA Novel Drug Approvals 2026 list, with the U.S. launch expected in the second half of this year. The pitch is simple: one shot a week instead of seven. For the […]
GLP-1s Just Got Stronger — Type 2 Diabetes Is Still Winning
Right now, in New Orleans, 12,000 of the world’s top diabetes researchers are gathered at the ADA 2026 Scientific Sessions. The headlines pouring out of that meeting this week are dominated by one thing: GLP-1 drugs got bigger. The 25 mg dose of the latest incretin therapies produced larger A1c reductions. More weight loss. Better […]